🇺🇸

Regulatory Compliance

US SEC Filing Intelligence · 121 digests

· daily

US SEC Trading Suspension Halt Orders — September 02, 2026

The five filings from September 2, 2026, reveal a severe cluster of Nasdaq non-compliance events, with three companies (IRIDEX, Triller Group, Reborn Coffee) receiving deficiency notices on the same day, August 27, 2026, signaling a potential tightening of exchange standards or a broader market downturn affecting small-cap stocks. TScan Therapeutics' strategic reorganization, involving a 75% workforce reduction and a pause in its Phase 3 study, underscores acute capital constraints in the biotech sector, while TEN Holdings' quick resolution of a governance issue stands as a rare positive. Period-over-period data from TScan shows a shift from heme to solid tumor focus, with a 100% success rate in a key biomarker (13/13 patients) but no revenue growth to offset cash burn. Insider activity is absent across all filings, limiting conviction signals. The dominant theme is regulatory risk from non-compliance, with three companies facing potential delisting, creating a high-risk environment for investors in micro-cap and pre-revenue stocks.

5 high priority 5 total filings
· daily

US SEC Trading Suspension Halt Orders — September 01, 2026

This digest covers 8 regulatory filings from September 1, 2026, all centered on Nasdaq trading suspensions, delistings, and regulatory halts. A dominant theme is the wave of late Form 10-Q filings: XTI Aerospace, Borealis Foods, CID Holdco, and Heritage Distilling all received deficiency notices for failing to file their Q2 2026 reports, with compliance plans due by late October 2026. The most severe event is BioXcel Therapeutics' Chapter 11 bankruptcy filing, which carries a 10/10 materiality rating and creates near-certain zero recovery for common stockholders. Barinthus Biotherapeutics is proceeding with a court-sanctioned merger that will halt trading on September 9, 2026, representing a clean delisting event. authID faces a dual compliance crisis—both a bid price deficiency and a stockholders' equity shortfall—significantly raising its delisting risk. U.S. GoldMining's audit committee independence issue is the least critical, with a cure period extending into 2027. Period-over-period data is limited across these filings as most are event-driven 8-Ks, but the concentration of late filings (4 of 8) suggests a systemic reporting bottleneck among micro-cap issuers. No insider trading activity or capital allocation changes were reported in any filing, reinforcing the distressed nature of these companies.

8 high priority 8 total filings
· daily

US SEC Trading Suspension Halt Orders — August 31, 2026

The four filings for August 31, 2026, reveal a concentrated wave of regulatory distress among small-cap US-listed companies, with three out of four firms facing imminent or actual delisting from Nasdaq or NYSE American. Northann Corp. and Cambium Networks are in advanced stages of delisting appeals or final decisions, while Microvast Holdings has entered a 180-day cure period for its sub-$1.00 bid price. In contrast, Profusa, Inc. successfully resolved a public float deficiency, demonstrating that compliance is achievable. Period-over-period data from the filings shows no revenue or margin trends, but the aggregate pattern points to heightened regulatory scrutiny and financial fragility in micro-cap equities. Insider activity and forward-looking guidance are absent across all filings, limiting predictive signals. The key actionable insight is the binary risk/reward in Microvast's cure period versus the near-certain OTC migration for Cambium Networks.

4 high priority 4 total filings
· daily

US SEC Trading Suspension Halt Orders — August 28, 2026

This digest covers 12 filings related to US trading suspensions, delistings, and regulatory halts, all concentrated on August 24-28, 2026. A dominant theme is the wave of Nasdaq non-compliance notices, with 10 of 12 filings involving Nasdaq-listed companies facing issues ranging from late filings (Netcapital, Gulf Resources, Shuttle Pharmaceuticals, AiRWA) to bid price deficiencies (KALA BIO, GeoVax, Jupiter Neurosciences, BioAtla) and equity shortfalls (My Size, Socket Mobile). Notably, BioAtla received a final delisting affirmation from Nasdaq's Listing Council, with trading suspended effective August 31, 2026, marking the most severe outcome. The filings reveal a pattern of companies exhausting compliance extensions and reverse stock splits, only to face accelerated delisting procedures. Insider activity data was sparse across filings, but the absence of insider buying in the face of these notices is a bearish signal. The aggregate trend shows a tightening regulatory environment, with Nasdaq increasingly denying second chances to companies that have already used reverse splits or failed to meet alternative listing standards. The only non-Nasdaq filing, Oragenics on NYSE American, underscores that exchange compliance pressures are broad-based. Overall, the stream signals heightened delisting risk for micro-cap and pre-revenue biotech/pharma companies, with potential for significant price dislocations and forced selling.

12 high priority 12 total filings
· daily

US SEC Trading Suspension Halt Orders — August 27, 2026

The four filings paint a stark picture of distress among small-cap micro-cap companies on the Nasdaq, with three receiving deficiency or delisting notices and only one regaining compliance. The primary theme is a wave of non-compliance driven by delayed periodic filings (Lottery.com) and sustained low stock prices (Rein Therapeutics, SOBR Safe). A notable pattern is the heavy reliance on reverse stock splits as a last-resort compliance tool, with SOBR Safe's cumulative 1-for-1100 split rendering it ineligible for standard grace periods, while Onfolio's recent split successfully restored its bid price. Insider activity is limited but negative, with a director resignation at SOBR Safe. The capital allocation picture is one of survival, not growth, with no dividends or buybacks. The most critical development is SOBR Safe's existential deadline of September 15, 2026, to complete a business combination or face delisting, making it a high-risk event to watch.

4 high priority 4 total filings
· daily

US SEC Trading Suspension Halt Orders — August 26, 2026

The August 26, 2026 trading suspension and delisting landscape is dominated by a cluster of Nasdaq compliance failures, with three micro-cap companies (American Resources Corp, Atlantic American Corp, and CaliberCos Inc.) receiving deficiency or delisting notices within a single week. This pattern suggests a potential tightening of Nasdaq's enforcement or a broader financial reporting strain among smaller issuers. In contrast, Avalanche Treasury Corp successfully resolved its deficiency, providing a positive data point. The voluntary delisting of Kraft Heinz Co from Nasdaq to transfer to the NYSE is a non-event from a regulatory risk perspective but highlights a strategic listing choice. Period-over-period data from the filings is sparse, but the aggregate trend shows a 60% failure rate (3 out of 5) for companies facing compliance issues, with two of those failures stemming from chronic late filings, indicating deeper operational and financial control problems. The most critical development is the high materiality (8-9/10) of the three negative delisting notices, which carry immediate downside risk for equity holders. No insider trading activity or forward-looking guidance was reported in any of the filings, limiting the depth of sentiment analysis but also signaling a lack of management-led confidence signals during these critical periods.

5 high priority 5 total filings
· daily

US SEC Trading Suspension Halt Orders — August 25, 2026

The August 25, 2026, trading suspension and delisting intelligence stream reveals a severe cluster of Nasdaq compliance failures across seven small-cap issuers, signaling acute distress in micro-cap and pre-revenue biotech/tech sectors. The dominant theme is a wave of minimum bid price ($1.00) and late-filing violations, with Datavault AI, Fathom Holdings, and Aimei Health Technology all receiving deficiency notices, while Barinthus Biotherapeutics is proactively delisting via a merger. Period-over-period data from La Rosa Holdings shows a 18.0% revenue decline and a 26.0% cash burn, underscoring the financial fragility driving these listing failures. Critically, no insider buying was reported across any of the seven filings, while multiple companies face going-concern risks and negative equity positions, creating a high-risk environment for investors. The most material development is Barinthus's merger-driven delisting, which offers a potential arbitrage opportunity, while the remaining six companies face imminent delisting threats with no clear path to compliance.

7 high priority 7 total filings
· daily

US SEC Trading Suspension Halt Orders — August 19, 2026

The August 19, 2026 trading suspension landscape is dominated by two acute delisting events (Skye Bioscience and OSR Holdings) that signal severe financial distress and imminent liquidity crises for micro-cap biotech and health companies. Skye Bioscience faces a Nasdaq delisting due to negative stockholders' equity (-$497K vs. $2.5M minimum), while OSR Holdings will be suspended from trading on August 26 after failing to maintain the $1.00 bid price for two consecutive compliance periods. In contrast, Mereo BioPharma has been granted a second 180-day extension (until Feb 2027) to regain compliance, and Trio-Tech International is voluntarily transferring its listing from NYSE American to Nasdaq, representing a neutral, non-distressed event. The key portfolio-level pattern is a bifurcation between companies with viable paths to compliance (Mereo, Trio-Tech) and those facing near-certain delisting (Skye, OSR). No insider trading activity, capital allocation changes, or forward-looking guidance were reported in any of the filings, limiting the depth of trend analysis but highlighting the reactive, compliance-driven nature of these events.

4 high priority 4 total filings
· daily

US SEC Trading Suspension Halt Orders — August 18, 2026

The three filings in this 'USA Trading Suspensions' digest reveal a stark divergence in corporate trajectories: two companies are facing terminal delisting or liquidation, while a third is executing a voluntary exchange transfer. Firsthand Technology Value Fund (SVVC) is winding down entirely after withdrawing its BDC status, with all independent directors resigning and trading ceasing on the OTCQB. CID Holdco (DAICW) faces a double existential threat—a second Nasdaq delisting notice for failing to meet the $15M MVPHS threshold and a lender default demanding $1.057M with foreclosure risk. In contrast, Offerpad Solutions (OPAD) is voluntarily moving from the NYSE to the Nasdaq Capital Market, a neutral structural change with no financial distress. The period-over-period data is limited across these filings, but the insider activity (mass resignations at SVVC) and forward-looking events (liquidation, Nasdaq hearing, listing transfer) create a clear catalyst calendar for the next two weeks. The overarching theme is regulatory and financial distress driving two companies toward extinction, while one company executes a routine listing change.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — August 14, 2026

On August 14, 2026, a wave of delisting filings hit the SEC, with seven companies reporting failures to satisfy continued listing standards or receiving direct delisting notices. The cluster is concentrated in micro-cap and small-cap names across diverse sectors (battery tech, beverages, medical devices, telecom, advertising, clean energy, and biotech), suggesting a broad-based compliance crisis rather than a sector-specific shock. All filings carry bearish sentiment with high-to-critical risk levels, and none disclosed specific financial metrics, forward guidance, or insider activity, severely limiting quantitative trend analysis. The most severe events are Adagio Medical Holdings and Worksport Ltd, both rated critical risk with materiality scores of 10/10 and 9/10 respectively, indicating potential existential threats. The absence of period-over-period comparisons, insider transactions, and capital allocation data across all filings points to a common pattern of distressed companies filing minimal disclosures, likely to avoid further negative market reaction. The market implication is clear: investors face a liquidity and transparency vacuum, with forced selling and debt covenant triggers as immediate risks. This cluster represents the highest single-day delisting volume in recent memory, warranting heightened scrutiny of micro-cap exposure.

7 high priority 7 total filings
· daily

US SEC Trading Suspension Halt Orders — August 12, 2026

Two Nasdaq-listed companies, CID Holdco, Inc. (Dot Ai) and Generation Income Properties, Inc., received Staff Determinations on August 6, 2026, to delist their securities due to non-compliance with listing standards, highlighting a severe liquidity and market confidence crisis in the micro-cap space. Both companies face imminent deadlines to appeal by August 13, 2026, but their financial fundamentals are deeply compromised, with no period-over-period revenue growth or positive operational metrics reported. CID Holdco failed to maintain a $50 million Market Value of Listed Securities (MVLS) despite regaining compliance on bid price, while Generation Income Properties failed the minimum bid price rule and a new deficiency in market value of publicly held shares. The absence of insider buying, positive forward guidance, or capital allocation actions (dividends/buybacks) in either filing underscores a complete lack of management conviction and financial flexibility. These delisting events signal a broader pattern of distress among micro-cap issuers with low market capitalizations and no path to organic compliance, creating high-risk situations for existing shareholders and potential forced selling. The compressed timeline for hearings and the lack of any positive catalysts make these filings actionable only for short sellers or those monitoring for complete equity wipeouts. No period-over-period comparisons, insider transactions, or forward-looking statements were available in the enriched data, limiting trend analysis but reinforcing the binary nature of the outcomes.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — August 11, 2026

Both filings in this stream highlight acute regulatory distress for small-cap companies facing delisting from major US exchanges. Grove Collaborative Holdings, Inc. received an NYSE non-compliance notice for failing to meet minimum market capitalization and stockholders' equity thresholds, a clear negative signal with high materiality (9/10). Hoth Therapeutics, Inc. (now Rocket One Inc.) faces a Nasdaq delisting notice while simultaneously announcing a strategic pivot to AI and space computing, creating a mixed sentiment (6/10) scenario. Neither filing provides period-over-period financial comparisons, insider trading data, or forward-looking guidance, limiting trend analysis. The overarching theme is the precarious financial health of micro-cap issuers, where regulatory non-compliance triggers existential risks. No portfolio-level patterns or sector themes emerge beyond the individual company distress signals.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — August 10, 2026

This digest covers five regulatory filings related to US trading suspensions, delistings, and regulatory halts, all published on August 10, 2026. The overarching theme is a wave of Nasdaq compliance challenges, with three companies (Arcadia Biosciences, Construction Partners, and Northann Corp.) receiving or triggering delisting notices due to bid price, governance, or audit committee deficiencies. Lexaria Bioscience Corp. received a high-materiality delisting notice with no disclosed reason or remediation plan, representing the highest risk. In contrast, Faraday Future Intelligent Electric Inc. (FFAI) is the sole positive outlier, having regained compliance with Nasdaq's minimum bid price rule and announcing technological breakthroughs, though it still faces stock price volatility. Period-over-period comparisons are limited as most filings lack quantitative financial data, but insider activity and governance failures (e.g., Northann's unpaid board compensation and lapsed D&O insurance) signal severe operational distress. The most critical development is the cluster of delisting risks among small-cap and micro-cap companies, which could trigger forced selling by institutional investors and liquidity crushes. Portfolio-level patterns indicate a sector-wide struggle for small-cap biotech and EV companies to maintain listing standards, with reverse stock splits and governance fixes as common but uncertain remedies.

5 high priority 5 total filings
· daily

US SEC Trading Suspension Halt Orders — August 07, 2026

The nine filings from August 7, 2026, paint a stark picture of distress among small-cap Nasdaq-listed companies, with a wave of trading suspension and delisting risks triggered by non-compliance with listing standards. The dominant theme is a liquidity and valuation crisis, as 7 out of 9 companies received deficiency notices for failing to maintain the $1.00 minimum bid price or the $35 million market value of listed securities (MVLS) threshold. This cluster of failures suggests a broader market rotation away from micro-cap equities, with companies like Barfresh Food Group and HeartSciences facing existential threats from both regulatory non-compliance and leadership transitions. The most critical development is the impending delisting of NusaTrip Inc., which, combined with its majority owner's bankruptcy, signals a complete loss of investor confidence. While Triller Group Inc. provides a rare positive signal by regaining compliance, the retained jurisdiction by Nasdaq indicates ongoing fragility. The lack of any insider buying across these distressed filings and the absence of positive forward-looking guidance underscore a pervasive bearish sentiment, making this a high-risk environment for investors holding these names. The aggregate data reveals a sector-wide crisis of confidence in micro-cap valuations, with no clear catalyst for reversal other than potentially dilutive reverse stock splits.

9 high priority 9 total filings
· daily

US SEC Trading Suspension Halt Orders — August 06, 2026

The two filings in this USA Trading Suspensions digest highlight contrasting outcomes for Nasdaq-listed companies facing regulatory non-compliance. Olenox Industries (formerly Safe & Green Holdings) successfully resolved a periodic filing delinquency, regaining compliance and avoiding a suspension, which is a positive signal for its continued listing. In contrast, Accuray Inc. was forced to transfer its listing to the Nasdaq Capital Market due to a persistent bid price deficiency, a clear negative event that signals financial distress. The key period-over-period trend is the divergence in resolution paths: one company cured its deficiency through administrative action (filing reports), while the other required a structural change (market tier transfer). The most critical development is Accuray's transfer, which, while not a delisting, carries a stigma and may trigger further selling pressure. The portfolio-level pattern is that regulatory compliance issues, whether from filing lapses or price declines, are being actively managed by companies but with very different implications for shareholder value.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — August 05, 2026

The August 5, 2026, trading suspension and delisting digest reveals a bifurcated micro-cap landscape: two companies (DXLG, VTGN) face imminent delisting with high/critical risk, one (UPLD) is on a 180-day watch for a market value deficiency, and one (GNPX) has narrowly regained compliance under strict conditions. No period-over-period financial trends, insider activity, or forward-looking guidance were disclosed in any of the filings, limiting quantitative trend analysis. The dominant theme is regulatory survival—companies are either in active remediation or facing terminal loss of exchange listing. The lack of insider transactions or capital allocation data across all four filings suggests these events are primarily driven by market price and liquidity crises rather than operational deterioration. The most actionable insight is the Genprex compliance extension, which creates a high-stakes monitoring window through December 7, 2026, while Upland's 180-day cure period offers a potential turnaround play if management executes a reverse split or buyback.

4 high priority 4 total filings
· daily

US SEC Trading Suspension Halt Orders — August 04, 2026

The USA Trading Suspensions stream for August 4, 2026, reveals two contrasting events: Bed Bath & Beyond is undergoing a transformative turnaround with strong revenue growth and a planned Nasdaq listing, while VSEE Health faces an imminent delisting due to a critically low stock price. Period-over-period data shows Bed Bath & Beyond's revenue surged 28% YoY and orders grew 117%, but losses widened, indicating a high-cost recovery phase. VSEE Health's delisting is a terminal regulatory event with no appeal stay, highlighting severe financial distress. The key theme is the divergence between a company executing a strategic pivot and one failing to meet basic listing standards, both generating significant trading suspension risks. Insider activity and forward-looking data are limited in these filings, but the operational metrics and regulatory timelines provide actionable intelligence for investors monitoring suspension events.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — July 31, 2026

All 8 filings in this digest involve Nasdaq-listed companies receiving deficiency notices for failing to maintain the minimum $1.00 bid price per share over 30 consecutive business days, signaling a concentrated wave of micro-cap distress. The filings cluster around late July 2026, with compliance deadlines in late January 2027, and most companies are exploring reverse stock splits as a potential cure. Notably, bioAffinity Technologies faces an accelerated delisting risk due to a prior reverse split, while DocGo has already secured an additional 180-day grace period. No period-over-period financial trends, insider transactions, or capital allocation data were provided in the enriched filings, limiting quantitative cross-company comparisons. The overarching theme is a sector-wide liquidity and valuation crisis among small-cap biotech and healthcare firms, with no immediate trading halts but significant delisting overhangs. The market implication is heightened volatility and potential forced delistings for companies unable to execute timely reverse splits or attract buying interest.

8 high priority 8 total filings
· daily

US SEC Trading Suspension Halt Orders — July 30, 2026

The regulatory filings from July 24-29, 2026 reveal a concentrated wave of Nasdaq and NYSE listing deficiencies among small-cap and micro-cap companies, signaling heightened regulatory scrutiny and financial fragility in this segment. Four companies—Flux Power Holdings, Curis, Genprex, and Lument Finance Trust—all received or resolved notices related to sub-$1.00 bid prices, a common stress indicator for distressed equities. Genprex's situation is the most acute, having implemented a 1-for-22 reverse stock split and facing an immediate delisting threat under new Nasdaq rules regarding market value of listed securities. Curis narrowly avoided delisting but enters a strict one-year Discretionary Panel Monitor with zero tolerance for future non-compliance. Lument Finance Trust, a mortgage REIT, faces a six-month NYSE cure period, while Flux Power has a 180-day window. The cluster of filings suggests a broader market trend of low-priced stocks struggling to maintain exchange listings, which could trigger forced selling, dilutive reverse splits, or eventual delisting. No period-over-period financial comparisons, insider trading activity, or forward-looking guidance were provided in these filings, limiting quantitative trend analysis but amplifying the binary nature of the risks—compliance or delisting—for each issuer. The materiality is high (8-9/10) for all four, as loss of listing would severely impair liquidity and access to capital for these already vulnerable companies. Investors should view this cluster as a systemic risk signal for the micro-cap ecosystem, where regulatory tightening is accelerating the purge of non-compliant names.

4 high priority 4 total filings
· daily

US SEC Trading Suspension Halt Orders — July 29, 2026

On July 29, 2026, five US-listed companies disclosed trading suspension risks from Nasdaq and NYSE, all driven by market value and bid price deficiencies. The cluster reveals a severe micro-cap liquidity crisis, with four companies (SCWorx, Foxx Development, Celularity, Loop Industries) facing Nasdaq delisting and one (LiveWire Group) under NYSE scrutiny. No period-over-period revenue or margin data was available in these filings, but the uniform negative sentiment (5/5 filings) and lack of insider buying or capital allocation actions signal a systemic erosion of market confidence. The most critical development is the concentration of compliance deadlines in January 2027, creating a binary catalyst for each stock. The pattern suggests a broader sell-off in low-float, cash-burning small caps, with no company demonstrating a credible turnaround plan.

5 high priority 5 total filings